Références
1.
Walker, A.E., M. Robins, and F.D. Weinfeld,
Epidemiology of brain tumors: the
national survey of intracranial neoplasms.
Neurology, 1985.
35
(2): p. 219-26.
2.
Percy, A.K., et al.,
Neoplasms of the central nervous system. Epidemiologic
considerations.
Neurology, 1972.
22
(1): p. 40-8.
3.
Pienkowski, T. and C.C. Zielinski,
Trastuzumab treatment in patients with breast
cancer and metastatic CNS disease.
Ann Oncol, 2010.
21
(5): p. 917-24.
4.
Tsukada, Y., et al.,
Central nervous system metastasis from breast carcinoma. Autopsy
study.
Cancer, 1983.
52
(12): p. 2349-54.
5.
Soffietti, R., et al.,
EFNS Guidelines on diagnosis and treatment of brain
metastases: report of an EFNS Task Force.
Eur J Neurol, 2006. 13(7): p. 674-81.
6.
Mut, M.,
Surgical treatment of brain metastasis: A review.
Clin Neurol Neurosurg,
2011.
7.
Modha, A., S.R. Shepard, and P.H. Gutin,
Surgery of brain metastases--is there still a
place for it?
J Neurooncol, 2005.
75
(1): p. 21-9.
8.
Kocher, M., et al.,
Adjuvant whole-brain radiotherapy versus observation after
radiosurgery or surgical resection of one to three cerebral metastases: results of the
EORTC 22952-26001 study.
J Clin Oncol, 2011.
29
(2): p. 134-41.
9.
Pollock, B.E., et al.,
Properly selected patients with multiple brain metastases may
benefit from aggressive treatment of their intracranial disease.
J Neurooncol, 2003.
61
(1): p. 73-80.
10.
Slamon, D.J., et al.,
Human breast cancer: correlation of relapse and survival with
amplification of the HER-2/neu oncogene.
Science, 1987.
235
(4785): p. 177-82.
11.
Slamon, D.J., et al.,
Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2.
N Engl J Med, 2001.
344
(11):
p. 783-92.
12.
Bendell, J.C., et al.,
Central nervous system metastases in women who receive
trastuzumab-based therapy for metastatic breast carcinoma.
Cancer, 2003.
97
(12): p.
2972-7.
13.
Kallioniemi, O.P., et al.,
Association of c-erbB-2 protein over-expression with high
rate of cell proliferation, increased risk of visceral metastasis and poor long-term
survival in breast cancer.
Int J Cancer, 1991.
49
(5): p. 650-5.
14.
Pestalozzi, B.C., et al.,
Identifying breast cancer patients at risk for Central
Nervous System (CNS) metastases in trials of the International Breast Cancer Study
Group (IBCSG).
Ann Oncol, 2006. 17(6): p. 935-44.
15.
Dawood, S., et al.,
Defining prognosis for women with breast cancer and CNS
metastases by HER2 status.
Ann Oncol, 2008. 19(7): p. 1242-8.
16.
Hicks, D.G., et al.,
Breast cancers with brain metastases are more likely to be
estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress
HER2 or EGFR.
Am J Surg Pathol, 2006.
30
(9): p. 1097-104.
17.
Dawood, S., et al.,
Incidence of brain metastases as a first site of recurrence among
women with triple receptor-negative breast cancer.
Cancer, 2012.
118
(19): p. 4652-9.
